| 41.31 Delayed Data As of Apr 18 |  +0.22 / +0.54%Today’s Change | 37.43 Today|||52-Week Range 45.62 | -4.84% Year-to-Date |
| Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study Apr 17 / Zacks.com - Paid Partner Content | Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth Apr 09 / Zacks.com - Paid Partner Content |
| Is Alnylam Pharmaceuticals a Buy Now? Apr 16 / MotleyFool.com - Paid Partner Content | Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Apr 09 / Zacks.com - Paid Partner Content |
| 3 Biotech Stocks That Doubled After Hitting Bottom in 2018 Apr 10 / MotleyFool.com - Paid Partner Content | Here's Why Dermira Shot Up 62% in March Apr 08 / MotleyFool.com - Paid Partner Content |
| Previous close | 41.09 |
| Today’s open | 41.25 |
| Day’s range | 40.77 - 41.47 |
| Volume | 1,575,659 |
| Average volume (3 months) | 1,018,294 |
| Market cap | $103.1B |
| Earnings growth (last year) | +19.94% |
| Earnings growth (this year) | +4.19% |
| Earnings growth (next 5 years) | +7.57% |
| Revenue growth (last year) | +2.83% |
| P/E ratio | 21.4 |
| Price/Sales | 2.68 |
| Price/Book | 1.53 |
| Today’s change | Today’s % change | |
|---|---|---|
| GSKGlaxoSmithKline | -0.13 | -0.33% |
| AZNAstraZeneca | +0.03 | +0.08% |
| ABBVAbbVie | -0.41 | -0.53% |
| NVONovo Nordisk | -0.12 | -0.25% |
| Next reporting date | April 26, 2019 |
| EPS forecast (this quarter) | $0.76 |
| Annual revenue (last year) | $40.7B |
| Annual profit (last year) | $5.1B |
| Net profit margin | 12.53% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
